Transdermal drug delivery system is a controlled drug delivery system in which the drugs can deliver through the skin portal to systemic circulation at a predetermined rate and maintain clinically the effective concentrations over a particular time. The advantages of transdermal drug delivery system are- prolonged therapeutic effect, prolonged duration action, Uniform plasma levels, administration of the complete dose, improved bioavailability, better patient compliance and easy termination of drug therapy. It is widely used for Neurological Disorders Pain Management, Hormone Replacement Therapy, Cardiovascular Diseases, Transdermal Estrogen Therapy, and Smoking Cessation. Transdermal Drug Delivery System is mainly segmented down by Transdermal Patches which includes Single-layer Drug-in-Adhesive, Multi-layer Drug-in-Adhesive, Reservoir, Matrix, Vapor Patch and Transdermal Semisolids that covers Ointments, Gels, Sprays, and others. Moreover, rising Prevalence of Chronic Disorders and Technological Advancements in Drug Delivery Systems anticipated for the growth of Global Transdermal Drug Delivery Systems.
AMA Research have segmented the market of Global Transdermal Drug Delivery System market by Type, Application and Region. On the basis of Type, Pain Management are dominating the market in the year 2020
On the basis of geography, the market of Transdermal Drug Delivery System has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2020.
Increasing Geriatric Population, Rising Prevalence of Chronic Disorders and Technological Advancements in Drug Delivery Systems
Collaboration between Pharmaceutical Companies and Drug Delivery Firms and Emerging Nations
- Side Effects of Systems at the Site of Application
In addition to the aforementioned factor, Increasing Geriatric Population
is expected to propel the growth of the market over the forecast period.
In February 2019 Hisamitsu Pharmaceutical Co., Inc., a leader in the manufacturing of transdermal patch has signed commercialization agreement with Kyowa Hakko Kirin Co., Ltd., a Japanese pharmaceutical and biotechnology company for HP-3000 product. The product a systemic transdermal Parkinsonís disease treatment patch developed by Hisamitsu Pharmaceuticalís TDDS (Transdermal Drug Delivery System) technologies for which Kyowa Hakko Kirin will be responsible for commercialization of the product.
The key Players profiled in the study are Hisamitsu Pharmaceutical Co., Inc. (Japan), Novartis AG (Switzerland), Mylan N.V. (United States), Johnson & Johnson Services, Inc. (United States), UCB S.A. (Belgium), Endo International, Inc. (Ireland), GlaxoSmithKline PLC (United Kingdom), Boehringer Ingelheim International GmbH (Germany), Acrux Limited (Australia) and Luye Pharma Group (China). A lot of United States players are profiled in the research study indicating a strong market dependence.